NO20054141L - 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse - Google Patents

2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse

Info

Publication number
NO20054141L
NO20054141L NO20054141A NO20054141A NO20054141L NO 20054141 L NO20054141 L NO 20054141L NO 20054141 A NO20054141 A NO 20054141A NO 20054141 A NO20054141 A NO 20054141A NO 20054141 L NO20054141 L NO 20054141L
Authority
NO
Norway
Prior art keywords
ring
group
medicament
optionally substituted
alkyl group
Prior art date
Application number
NO20054141A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054141D0 (no
Inventor
Alistair William Lochead
Mourad Saady
Franck Slowinski
Philippe Yaiche
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03290570A external-priority patent/EP1454910A1/en
Priority claimed from EP20030290571 external-priority patent/EP1454908B1/en
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of NO20054141D0 publication Critical patent/NO20054141D0/no
Publication of NO20054141L publication Critical patent/NO20054141L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20054141A 2003-03-07 2005-09-06 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse NO20054141L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03290570A EP1454910A1 (en) 2003-03-07 2003-03-07 Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives
EP20030290571 EP1454908B1 (en) 2003-03-07 2003-03-07 Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
PCT/EP2004/003050 WO2004078759A1 (en) 2003-03-07 2004-03-05 Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives

Publications (2)

Publication Number Publication Date
NO20054141D0 NO20054141D0 (no) 2005-09-06
NO20054141L true NO20054141L (no) 2005-12-07

Family

ID=32963795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054141A NO20054141L (no) 2003-03-07 2005-09-06 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse

Country Status (23)

Country Link
US (2) US7211581B2 (es)
EP (1) EP1603910B1 (es)
JP (1) JP4778890B2 (es)
KR (1) KR101072159B1 (es)
AR (1) AR043486A1 (es)
AT (1) ATE440844T1 (es)
AU (1) AU2004218249B2 (es)
BR (1) BRPI0408186A (es)
CA (1) CA2516934C (es)
CY (1) CY1111132T1 (es)
DE (1) DE602004022784D1 (es)
DK (1) DK1603910T3 (es)
EA (1) EA008595B1 (es)
ES (1) ES2332132T3 (es)
HK (1) HK1085742A1 (es)
IL (1) IL170468A (es)
MX (1) MXPA05009575A (es)
NO (1) NO20054141L (es)
NZ (1) NZ542136A (es)
PL (1) PL1603910T3 (es)
PT (1) PT1603910E (es)
SI (1) SI1603910T1 (es)
WO (1) WO2004078759A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP1992621A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992620A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
AU2003221500B9 (en) * 2002-02-28 2008-11-20 Mitsubishi Pharma Corporation Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
NZ542136A (en) 2008-07-31
CY1111132T1 (el) 2015-06-11
EP1603910A1 (en) 2005-12-14
AU2004218249A1 (en) 2004-09-16
DE602004022784D1 (de) 2009-10-08
MXPA05009575A (es) 2006-05-19
ES2332132T3 (es) 2010-01-27
US20060025417A1 (en) 2006-02-02
IL170468A (en) 2010-12-30
JP2006519813A (ja) 2006-08-31
JP4778890B2 (ja) 2011-09-21
US7452897B2 (en) 2008-11-18
CA2516934A1 (en) 2004-09-16
EA200501243A1 (ru) 2006-04-28
US20070167455A1 (en) 2007-07-19
KR101072159B1 (ko) 2011-10-10
EP1603910B1 (en) 2009-08-26
DK1603910T3 (da) 2009-11-23
SI1603910T1 (sl) 2009-12-31
WO2004078759A1 (en) 2004-09-16
US7211581B2 (en) 2007-05-01
AR043486A1 (es) 2005-08-03
HK1085742A1 (en) 2006-09-01
AU2004218249B2 (en) 2009-04-30
KR20050113218A (ko) 2005-12-01
CA2516934C (en) 2011-09-20
NO20054141D0 (no) 2005-09-06
PT1603910E (pt) 2009-10-30
PL1603910T3 (pl) 2010-02-26
BRPI0408186A (pt) 2006-04-04
ATE440844T1 (de) 2009-09-15
EA008595B1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
NO20054140L (no) Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
Göker et al. Synthesis and potent antibacterial activity against MRSA of some novel 1, 2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines
NO20054330L (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
NO20063187L (no) Substituerte 8'-pyri(mi)dinyl-dihydrospiro-[cykloalkylamin]-pyrimido[1,2-a]pyrimidin-6-on-derivater
EP2598480A1 (en) Cyclopropylamine derivatives useful as lsd1 inhibitors
AU2013366898B2 (en) Halogen-substituted heterocyclic compound
NO20054141L (no) 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse
NO20092373L (no) Substituerte heteroarylpyridopyrimidonderivater
WO2006022442A1 (ja) ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
Giles et al. Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
EA200400936A1 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
NO20080914L (no) Mellomprodukt for syntetisering av farmasoytisk middel og fremgangsmate for fremstilling av dette
Cheng et al. Synthesis of 5-methyl phenanthridium derivatives: A new class of human DOPA decarboxylase inhibitors
MX2009004884A (es) Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos.
Jiang et al. Discovery of 3-(4-sulfamoylnaphthyl) pyrazolo [1, 5-a] pyrimidines as potent and selective ALK2 inhibitors
Li et al. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors
BR0308106A (pt) Derivados de 1-[alquil], 1[(heteroaril)alquil] e 1-[(aril)alquil]-7-(pirimidin-4-il)-imidazo[1,2-a]pirimidin-5- (1h)-ona
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
WO2008053863A1 (fr) Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
PT1315730E (pt) Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona
ATE448214T1 (de) Neue 3-phenylpropionsäurederivate und ihre verwendung als ppar-gamma-rezeptorliganden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application